NR1H4 and metabolic dysfunction-associated steatotic liver disease: Compared with FXR-induced reductions in TAG levels via an FXR-SHP-SREBP1c de novo lipogenesis pathway, it has been shown that FXR activation protects against NAFLD via BA-dependent reductions in lipid absorption [205].